Results 201 to 210 of about 484,364 (380)

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Addressing blinding in classic psychedelic studies with innovative active placebos. [PDF]

open access: yesInt J Neuropsychopharmacol
Aday JS   +3 more
europepmc   +1 more source

d-Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment

open access: bronze, 1978
Daniël P. van Kammen   +4 more
openalex   +1 more source

Late‐Onset Spondylarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where TNF or IL‐17 Blockade may have a Therapeutic Role

open access: yesArthritis &Rheumatology, Accepted Article.
Background Polymyalgia rheumatica (PMR) is an age‐related inflammatory disease with shoulder‐hip girdle involvement. Magnetic resonance imaging (MRI) reveals extracapsular/entheseal soft tissue involvements in both PMR and spondyloarthritis (SpA) with sacroiliac joint and peri‐entheseal spinal bone marrow oedema (BMO) being characteristic of SpA ...
Kerem Abacar   +12 more
wiley   +1 more source

Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. [PDF]

open access: bronze, 1988
Yuichi Tazaki   +7 more
openalex   +1 more source

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy